ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Conditions: Breast Carcinoma Interventions: Combination Product: Endocrine therapy; Combination Product: Endocrine therapy combined with the local treatment of FES-negative lesions; Combination Product: Chemotherapy Sponsors: Institut Curie; Zionexa Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials